Catalyst Crew Technologies Corp. has filed a Current Report on Form 8-K with the U.S. Securities and Exchange Commission disclosing a material change in its business direction and corporate strategy. The company is transitioning from its prior business focus to become a development-stage artificial intelligence-enabled healthcare technology company, with an initial focus on Latin America and other emerging markets. A copy of the company's Form 8-K is available for review on the SEC's EDGAR database at https://www.sec.gov/Archives/edgar/data/1840439/000119312526068375/d95198d8k.htm.
The strategic shift represents a significant corporate realignment with potential implications for healthcare technology development in regions with growing demand for modernized healthcare delivery systems. The company's anticipated areas of focus include development of AI-driven healthcare software platforms, telehealth and remote patient monitoring technologies, clinical data analytics and interoperability systems, healthcare workflow and administrative automation solutions, and strategic acquisitions and partnerships within the healthcare technology sector. This transition comes as emerging markets increasingly seek scalable digital health solutions to improve access, efficiency, and care coordination.
In connection with its revised strategic direction, the company intends to change its corporate name to LataMed AI Corp. The proposed name change is expected to be effected through the filing of Articles of Amendment with the State of Nevada and is subject to required corporate approvals. Additionally, the company intends to submit a Company Related Action Notification Form and supporting documentation to the Financial Industry Regulatory Authority, requesting review and processing of both the corporate name change and a corresponding ticker symbol change. Neither the corporate name change for marketplace purposes nor any ticker symbol change will become effective until FINRA has completed its review and announces the effective date of the corporate action.
The company remains in the development stage of this strategic transition and is actively implementing its new plan of operations. There can be no assurance that the company will successfully implement its new business plan, secure financing, complete acquisitions, enter into definitive agreements, or generate revenues. The company is a development-stage enterprise and has not generated revenues from its newly announced business direction. The company intends to continue meeting its reporting obligations under the Securities Exchange Act of 1934 and will provide updated disclosures through filings with the SEC and through OTC Markets Group, as applicable.
This strategic pivot to AI-enabled healthcare technology represents a notable development in the digital health landscape, particularly for emerging markets where healthcare infrastructure challenges persist. The company's focus on Latin America aligns with regional efforts to modernize healthcare delivery through technology integration. The planned name change to LataMed AI Corp. signals a rebranding effort to reflect this new strategic direction more clearly to investors and stakeholders. The company is in the process of developing a new corporate website that will reflect its updated business direction and branding and expects to provide additional updates as they become available.
